Vincent Roche

ADI CEO Roche sold 10,000 shares at $404.25 (scheduled 10b5-1 plan); retains 137,537 non-derivative shares plus 90,803 options

Vincent Roche, Chair & CEO, sold 10,000 shares of ADI at $404.25 on 2026-06-01 under a pre-arranged 10b5-1 trading plan adopted on 2025-12-03, a scheduled transaction not driven by discretionary timing. The sale reduced his non-derivative holdings by -6.8% to 137,537 shares while retaining 90,803 non-qualified stock options. Across his prior 5 trades at ADI, the 90-day returns averaged positive (ranging from +6.4% to +33.0%), though the most recent May 2026 sale yielded only +4.0% over 30 days. The current stock price of $437.67 is +0.4% from the 52-week high and +10.2% above the 30-day average, reflecting recent strength that may reflect broader market recovery rather than ticker-specific conviction.

ADI Chair & CEO Roche sells 60,000 shares for $24.4M across 4 transactions; retains 137,537 shares plus derivative holdings

Vincent Roche sold 60,000 shares (60.0K shares) totaling $24,358,405.91 across 4 separate transactions on 2026-05-22 and 2026-05-26 at prices ranging from $396.80 to $415.74, reducing his non-derivative holdings from 197,537 shares to 137,537 shares. His cross-ticker track record shows 20 prior sells with an average 90-day return of +13.4% and a 90d well-timed rate of 10.00%, indicating his prior sales have not typically preceded stock declines. At ADI specifically, all 5 of his prior sells posted positive 90-day returns (ranging from +6.4% to +33.0%), with a timing pattern of 0 of 5 being well-timed at the 90-day mark—meaning the stock rose after each prior sale. The stock currently trades at $437.67, approximately 0.4% from its 52-week high of $435.72, and has posted a 30-day return of +10.2% and 90-day return of +32.7% since the May transactions. Roche retains Performance-Based Stock Option holdings of 430,000 shares and 400,000 shares in his direct account, preserving significant upside exposure.

ADI CEO Vincent Roche sells ~$4M in stock while simultaneously buying, signaling mixed conviction near 52-week highs.

Vincent Roche, Analog Devices' Chair & CEO, executed a dual transaction on the same day: purchasing shares while simultaneously selling a substantially larger block at nearly four times the purchase price. The sale occurred when the stock was trading near its 52-week highs and had already climbed sharply over the preceding months, suggesting Roche may be taking profits after significant appreciation rather than expressing confidence in further upside. The simultaneous buy is notable but modest in comparison, and could reflect routine equity compensation vesting or rebalancing rather than fresh conviction. For a CEO with direct operational knowledge, this pattern—profit-taking at elevated valuations—is more cautionary than bullish, particularly given the company's stretched valuation relative to its fundamentals.

ADI CEO Roche Vincent sold 10,000 shares at $318.14 (April 1, 2026); stock down -6.1% in 30 days, -11.8% from 52-week high.

Roche Vincent, Chair & CEO of Analog Devices, sold 10,000 shares for $3,181,400 on 2026-04-01, reducing his holdings from 177,825 to 167,825 shares (-5.6% of pre-transaction position). The sale occurred at $318.14, and the stock has since declined -6.1% over 30 days and sits -11.8% below its 52-week high of $360.80. His prior trades at ADI show a mixed timing pattern: 0 of 3 prior sales measured at the 90-day mark were well-timed (stock rallied after each sale), most recently including a +15.7% 90-day return on the January 2026 sale and +32.3% on the November 2025 sale. The current sale follows the pattern of frequent dispositions at this ticker and occurs in a period of moderate stock weakness, though fundamentals remain robust with FY revenue growth of +16.9% and a market cap of $155.4B.

Chair & CEO Vincent Roche sold 10,000 ADI shares at $350.00 on 2026-03-02 for $3.5M

Vincent Roche, Chair & CEO of Analog Devices, sold 10,000 shares at $350.00 on 2026-03-02, reducing his holdings by 6.0% to 155.7K shares. The sale occurred near ADI's 52-week high of $360.80, with the stock currently trading at $338.99. Within ADI specifically, Roche's prior five trades show a mixed timing pattern: two trades measurable at 90 days showed positive returns (well-timed sells would show negative 90d returns), and his cross-ticker track record across all tickers shows a 11.76% well-timed rate on 20 prior sells. The stock is up 9.0% over 30 days and 21.8% over 90 days from the transaction date, suggesting this sale was not well-timed against subsequent price movement. ADI fundamentals remain strong with $3.2B quarterly revenue, $830.8M net income, and 16.9% annual revenue growth, though the P/E of 61.19 reflects elevated valuation expectations.

CEO Vincent Roche sold 10,000 ADI shares at $306.92; still holds 155,688 shares post-sale.

Vincent Roche, Chair & CEO, sold 10,000 shares of Analog Devices on 2026-02-02 at $306.92, reducing his holdings by 6.0% to 155,688 shares remaining. At current price of $311.29, ADI has gained 13.7% in the past 30 days and 31.9% over 90 days, signaling strong momentum post-trade. Notably, Roche's prior trades at ADI show a 0 of 3 well-timed rate at the 90-day mark, and his cross-ticker track record exhibits only an 11.11% well-timed rate across 20 prior sells with an average 90-day return of +10.4%—indicating his sales have historically coincided with stock appreciation rather than declines. The sale occurs as ADI trades near its 52-week high ($318.70), down just 2.3% from that peak, in a company generating $2.9B quarterly revenue with 16.9% annual growth and a 58.84 P/E ratio.

CEO Vincent Roche sold 10,000 ADI shares at $275.07 on 2026-01-02; retains 155.7K shares. Stock at $277.29.

Roche sold 10,000 shares (6.0% of his pre-transaction holding) for $2.75M on January 2, 2026, near the 52-week high of $283.39. At his 5 prior trades at ADI, he has achieved only 1 well-timed sell at the 90-day mark (20% success rate on same-ticker history), compared to his cross-ticker track record of 11.11% well-timed rate across 20 prior sells. The stock has gained 18.6% over the past 90 days and is currently trading at $277.29, just 2.2% below its 52-week high. He retains substantial holdings of 155.7K shares at the company where he serves as Chair and CEO, suggesting no underlying conviction shift rather than a discrete rebalancing event.

ADI Chair & CEO Vincent Roche sells 10,000 shares at $282.42; stock near 52-week high of $283.39

Chair & CEO Roche Vince sold 10,000 shares (10.0K shares) of ADI at $282.42 on 2025-12-12, reducing holdings by 6.0% to 155,688 shares (155.7K shares). The sale occurred near the 52-week high of $283.39 (-1.0% from peak), during a period of strong momentum: the stock rose 19.4% over 30 days and 14.9% over 90 days. His prior trades at ADI show mixed timing: 2 of 3 measurable 90-day outcomes were well-timed (negative returns following sales), but his cross-ticker track record shows only 11.11% well-timed rate across 20 prior sells—meaningfully below 50%, indicating historically poor sell timing. The company reports robust fundamentals: $2.9B quarterly revenue (+16.9% annual growth) and $518.5M net income, with a $137.3B market cap, though the P/E of 53.01 reflects elevated valuation expectations. The transaction signals no directive pattern; without details on scheduling or strategic rationale, the sale at peak price warrants observation against future price action and any subsequent executive transactions.

ADI Chair & CEO Roche Vincent sold 10,000 shares at $234.95; stock down 10.3% from 52-week high, prior sells mixed

ROCHE VINCENT sold 10,000 shares (10.0K shares) of Analog Devices at $234.95 on 2025-11-03, reducing his stake by 5.8% to 163,640 shares (163.6K shares). The stock has declined 10.3% from its 52-week high of $255.63 and is currently trading at $229.38, below the transaction price. His prior five trades at ADI show mixed outcomes: three recent sells (October, September, August) declined modestly in the 30 days following the sale, while his May 2025 sale was followed by gains (+8.7% at 30 days, +17.4% at 90 days). The company is trading at a P/E of 57.63 and reported annual revenue growth of -23.4%, reflecting a challenging operating environment. This sale occurs amid broad weakness in the stock price and warrants observation of whether the pattern of September-through-October divestitures signals portfolio management amid sector headwinds.

ADI Chair & CEO Roche Vincent sells 10,000 shares at $243.71; stock down 2.7% in 30 days.

Roche Vincent, Chair & CEO of Analog Devices, sold 10,000 shares at $243.71 on 2025-10-01, reducing his holdings from 150.1K to 140.1K shares. The stock has declined 2.7% in the 30 days following the trade, consistent with his recent selling pattern at ADI—three prior sales in August and September also saw modest negative 30-day returns (-2.0%, -2.9%, -2.4%). However, his longer-term track record at ADI shows mixed timing: prior measurable outcomes (90-day window) yielded gains of +17.4% and +18.9%, suggesting his sales did not consistently precede declines. His cross-ticker open-market history reveals a 11.76% well-timed rate across 20 prior sells, indicating only modest predictive accuracy. Against this backdrop, the sale occurs when ADI trades 5.5% below its 52-week high and carries a P/E of 60.72, while annual revenue growth shows -23.4%.